StudyFinder
Search Results Within Category "Heart and Vascular"
Suggestions within category "Heart and Vascular"
Advanced Heart Failure and Transplant
Angina
Arrhythmias
Cardiac Rehabilitation
Coronary Artery Disease
Heart Structure Defect/Congenital Heart Defect
Heart Valve Research
Hypertension
LVAD
Peripheral Artery Disease
Preventative Cardiology
Pulmonary Embolism
2 Study Matches
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction with VISITAG SURPOINT Module for the treatment of symptomatic drug refractory paroxysmal atrial fibrillation (A nested sub-study of REAL AF registry)
The purpose of this research is to provide additional information about safety and effectiveness of the VISITAG SURPOINT Module with external processing unit (EPU) when used with QDOT Micro? System.
Contact(s):
Briita Wanhala - bwanhal1@hfhs.org
Principal Investigator: Arfaat Khan
Principal Investigator ID: akhan2@hfhs.org
Sex: Male or Female
Age: 18 years and over
Phase: N/A
Healthy Volunteers:
Inclusion Criteria:
• 18 years of age or older
• Symptomatic atrial fibrillation refractory to antiarrhythmic drugs (AADs)
• Scheduled or have undergone an atrial fibrillation ablation usint the QDOT Micro? System
Exclusion Criteria:
• Patients who have undergone catheter ablation for atrial fibrillation (PVI, roof line, posterior wall ablation...)
• Persistent or long-standing persistent atrial fibrillation
Interventions: Drug/Device: QDOT Micro? System
Conditions: Atrial Fibrillation
Keywords: Ablation, Anti-Arrhythmic medications, Atrial Fibrillation
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation (REACT-AF)
This research is being done to assess whether it is safe and effective to stop oral anticoagulation medications (a blood-thinning medication) during prolonged periods of normal heart rhythm in participants with infrequent episodes of atrial fibrillation (AF)
Contact(s):
Briita Wanhala - bwanhal1@hfhs.org
Principal Investigator: Marc Lahiri
Principal Investigator ID: mlahiri1@hfhs.org
Sex: Male or Female
Age: 18 years and over
Phase: III
Healthy Volunteers:
Inclusion Criteria:
• 22-85 years of age
• History of non-permanent atrial fibrillation on anti-coagulants
• CHA2DS2-VASC score of 1-4 for men and 2-4 for women without prior stroke or TIA
Exclusion Criteria:
• Any documented single AF episode lasting ?1 hour on within 45 days prior to randomization
• Existing cardiac rhythm device or indication for a permanent pacemaker, ICD or CRT.
• Participant needs DOAC for reasons other than preventing stroke or arterial embolism resulting from atrial fibrillation.
• Stage 4 or 5 chronic kidney disease
Interventions: Drug/Device: AF-sensing Smart Watch (AFSW)
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation, Blood thinners